To establish the analytical accuracy of the assay three sets of samples, cell lines with previously documented mutations in BRAF or KRAS, synthetic oligonucleotides containing all mutations detected by the KBN-SNPE assay and a set of 60 FFPE tumor samples were analyzed by both the KBN-SNPE assay and Sanger sequencing. The gene discussed is BRAF; the disease is neoplasm.